A groundbreaking step forward for a rare bleeding disorder — but does it finally bring hope to those living with HHT?
A new clinical trial has made waves in the medical community. Researchers at Mass General Brigham have discovered that a drug known as engasertib could significantly reduce bleeding episodes in patients suffering from hereditary hemorrhagic telangiectasia (HHT), a condition that has long lacked any approved treatment. But here’s where things get interesting — while these early results look promising, experts warn that more research is still needed before calling it a cure.
HHT, the world’s second most common inherited bleeding disorder, affects roughly one in every 3,800 people. Patients often deal with persistent, sometimes debilitating nosebleeds, along with internal bleeding and malformed blood vessels in critical organs such as the brain, lungs, and liver. These abnormalities can trigger strokes, heart failure, and even brain hemorrhages — severe complications that drastically reduce quality of life. Despite the magnitude of its impact, there has been no FDA-approved therapy, leaving patients to manage symptoms rather than address the underlying cause.
That may soon change. In a double-blind, placebo-controlled study published in the New England Journal of Medicine, researchers tested engasertib—an experimental oral drug designed by Vaderis Therapeutics—to determine its safety and effectiveness. The trial involved 75 adults living with HHT, divided into three groups: one taking 30 milligrams of engasertib daily, another receiving 40 milligrams, and a third on placebo, all over a 12-week period.
The findings? Remarkably hopeful. Patients treated with engasertib experienced shorter and less frequent episodes of nosebleeding compared to those on placebo. Even more striking, 61% of participants in the 40-milligram group and 37% in the 30-milligram group reported feeling "much better" after 12 weeks — while only 27% of those on placebo said the same. As for side effects, they were mild: the most common being a temporary, easily reversible rash. Serious complications occurred at similar rates across all groups, reinforcing engasertib’s strong safety profile.
Dr. Hanny Al-Samkari, co-lead investigator of the study and hematologist at Massachusetts General Hospital, described the findings as a promising milestone. “HHT causes complex vascular problems throughout the body, often leading to dangerous blood vessel malformations. For years, we’ve had no FDA-approved solution,” he explained. “This trial moves us closer to a future where patients finally have an effective, targeted treatment option.”
To understand why engasertib works, it helps to look at the biological mechanism behind HHT. The disorder stems from genetic mutations that disrupt the ALK1 signaling pathway, which is crucial for healthy blood vessel formation. This malfunction triggers an excessive buildup of a protein called AKT — the very molecule engasertib is designed to inhibit. By selectively shutting down this overactive protein, the drug aims to restore balance to blood vessel growth and repair.
The study was fully funded by Vaderis Therapeutics and co-designed by the company in collaboration with the academic researchers. Along with Dr. Al-Samkari, the author team included Pamela G. Hodges and numerous international collaborators such as Josefien Hessels, Sophie Dupuis-Girod, and Vicente Gómez del Olmo, showcasing a global effort to combat this underrecognized disease.
Still, the excitement comes with caution. Experts emphasize that while engasertib’s results are encouraging, large-scale and long-term studies will be crucial to confirm its benefits and ensure safety in diverse patient populations. After all, one question remains: could this be the long-awaited breakthrough — or just the first step toward it?
For now, optimism is in the air. Patients battling HHT, who have endured years of uncertainty and limited treatment options, finally have a reason to hope. But what do you think — should engasertib’s promise be celebrated as a breakthrough already, or do such early successes risk raising false hope before the science is fully settled? Share your thoughts below — this debate is just getting started.
